Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead submits NDA for Quad Tablet
Following approval, the Quad will be the only once-daily, single-tablet regimen containing an integrase inhibitor. The submission of NDA was done on the back of positive data from
Following approval, the Quad will be the only once-daily, single-tablet regimen containing an integrase inhibitor. The submission of NDA was done on the back of positive data from
The therapeutic platform comprises a novel proprietary and IP-protected approach, which includes utilisation of a bacterial danger signal in combination with the patient’s tumour antigens to mobilise the
Study 101 evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, while Study 102 assessed multiple-dosing of PEGPH20 in combination with dexamethasone. The results
Rusnano is co-investing $25m in Bind and other $25m in Selecta. Bind and Selecta intend to strengthen their US-based operations by setting up subsidiaries in Russia to develop
The pharmacy automation solution is said to optimize medication ordering, dispensing, administration, charge capture, and inventory management processes. In addition, the medical center is also using McKesson’s ROBOT-Rx
Xpansion Interpreter is used to determine the number and location of AGG interruptions associated with expansion of the Fragile X gene and also helps in better understanding of
Under the terms of the deal, Aragen Bioscience will provide its clients access to Xoma’s Human Engineering technology for antibody humanization. The financial terms of the agreement have
The combination contains Bristol-Myers Squibb’s protease inhibitor Reyataz (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing agent which increases blood levels of certain HIV medicines to enable a dosing
The meeting will be held in San Francisco, US between 4 and 8 November 2011. The study intended to assess the efficacy of immune-modulator, recombinant human Interleukin-7 (CYT107).
The deal is expected to close this quarter, as Advion BioServices will join Quintiles as Advion Bioanalytical Labs, a Quintiles company. Quintiles Global Laboratories senior vice president Thomas